6 Results for "

Entity Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Entity Inhibitors" in MCE Product Catalog:

17
17 Cited Publications
Cat. No.: HY-117410
CAS No.: 1702967-37-0
Purity:  99.46%
Synonyms: PSMA-617
Research Areas:  

Cancer

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
loading...
    loading...
Cat. No.: HY-N6797
CAS No.: 71751-77-4
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead c-Met inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .
loading...
    loading...
Cat. No.: HY-172159
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

FF2039 (compound 1j) is a specific HDAC1, HDAC6, and HDAC isoforms of class I, IIa and IIb PROTAC degrader. FF2039 demonstrates s significant antiproliferative activity against both hematological and solid cancer cell lines, driven by cell cycle arrest and Apoptosis induction. FF2039 inhibits HDAC isoform of HDAC1, HDAC2, HDAC4 and HDAC6 with IC50s of 1.03, 2.15, 12.4 and 0.053 μM, respectively. FF2039 shows antiproliferative activity against different tumor entities of MM.1S, MDA-MB-231 and U-87MG with EC50s of 2.8, 28 and 30 μM, respectively. (Pink: PRMT5 ligand (HY-168864); Blue: E3 ligase ligand HY-W957284); Black: linker (HY-W881439); E3+linker (HY-172185 )) .
loading...
    loading...
Cat. No.: HY-N14941
CAS No.: 11031-15-5
Phleomycin G is a heteropeptide antibiotic. Phleomycin G has anti-Gram-positive bacteria, negative bacteria and mycobacterium effects. Phleomycin G extends the survival time of mice transplanted with Ehrman's ascites cancer. Phleomycin G inhibits airy entity carcinoma in mice .
loading...
    loading...
Cat. No.: HY-N14887
CAS No.: 11031-13-3
Phleomycin E is a heteropeptide antibiotic. Phleomycin E has anti-Gram-positive bacteria, negative bacteria and mycobacterium effects. Phleomycin E extends the survival time of mice transplanted with Ehrman's ascites cancer. Phleomycin E inhibits airy entity carcinoma in mice with an IC50 of 0.31 μg/mL .
loading...
    loading...
Cat. No.: HY-L0119V
3,253 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.